Application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus and hyperlipidaemia

A technology of glucuronic acid and hyperlipidemia, applied in the field of compounds, can solve problems not involved in the treatment of diabetic concomitant diseases or hyperlipidemia, and restricting the use of drugs

Active Publication Date: 2012-09-19
GUANGZHOU YUNZHONG BIOTECH
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since September 2010, Rosiglitazone Maleate, which is widely used, has been recommended to be suspended by the European Medicines Agency, the US Food and Drug Administration and the China State Food and Drug Administration because it may cause heart proble

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus and hyperlipidaemia
  • Application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus and hyperlipidaemia
  • Application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus and hyperlipidaemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The present invention will be further described below in conjunction with experiments and experimental data.

[0020] Pharmacodynamic experiment results of stickyronic acid A in SD rat type 2 diabetes animal model Animal grouping and administration: select diabetic male SD rats induced by high-sugar and high-fat diet and intraperitoneal injection of small dose of streptozotocin According to fasting blood glucose and body weight, they were evenly divided into model group, treatment group and positive control group. 8 in each group. Another 8 normal rats were followed for observation.

[0021] (1) Model group: equal volumes of mixed Tween-80 and dimethyl sulfoxide were diluted tenfold with distilled water, and injected intraperitoneally at 1 mL per 100 g body weight, once a day until the end of the experiment.

[0022] (2) Therapeutic group: Haginonic acid A was dissolved in equal volumes of mixed Tween 80 and dimethyl sulfoxide to prepare a 10 mg / mL stock solution. Be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus or hyperlipidaemia. Animal experiment data show that the pigeon pea ketonic acid A can remarkably reduce the serum triglyceride level, the total cholesterol level and the low-density lipoprotein cholesterol level of SD (Sprague-Dawley) rats with type-2 diabetes mellitus, and can treat or improve the hyperlipidaemia as an accompanied disease of the diabetes mellitus; and pathological research results prove that the pigeon pea ketonic acid A can reduce spotty necrosis of hepatocytes, can treat or improve liver injury as an accompanied disease of the diabetes mellitus, reverses injury to tissues of pancreas inlets of the rats due to glucoses, and has protection and repair effects on pancreas. The pigeon pea ketonic acid A can remarkably reduce the serum triglyceride level and the total cholesterol level of Zucker rats with congenital obesity, and is proved to be capable of treating or improving the hyperlipidaemia.

Description

technical field [0001] The present invention relates to a new application of compounds, in particular to the application of stringyaronic acid A and its pharmaceutically acceptable derivatives, especially the application of stringyaronic acid A and its pharmaceutically acceptable salts or esters in the preparation of drugs for diabetic concomitant disease or hyperlipidemia . Background technique [0002] Hyperlipidemia is the single or multiple levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the blood caused by lipid metabolism disorders that are higher than normal standards. The main harm of hyperlipidemia is to cause atherosclerosis. Arterial blockage causes long-term insufficient blood and oxygen supply to vital organs throughout the body, resulting in organic and functional damage to organs, leading to numerous related diseases. One of the most common fatal diseases is coronary heart disease. Hyperlipidemia is an ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P3/10A61P3/06A23L1/29A23L33/00
CPCA61K31/192A61K36/48A61P1/16A61P1/18A61P3/06A61P3/10A61P13/12
Inventor 沈小玲王璐胡英杰邱声祥符林春麦兆
Owner GUANGZHOU YUNZHONG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap